Version 1.0.3

Submission Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2015
Deadline Date	30/10/2015
Date Submitted	04/11/2015
Туре	Historic Performance in Initiating
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 23 of 23. Pages: 1

System generated field. Please check your dates if value is

638	638	Id] ;
63852 14/NW/1052	63851 14/LO/0121	Research Ethics Committee Reference Number	
2		Integrated Research Application System Number	
NHS Permission	NHS Permission	Submission Type	
B5371002: A Phase 3 Randomised, Double-Blind Study assessing the efficacy and safety of PF- 06438179 and Infliximab in combination with Methotrexate in subjects with moderately to severely active Rheumatoid Arthritis who have had an inadequate response to OSTRICH: A randomised double blind	PAKT - A phase II, double-blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with Paclitaxel in triple-negative advanced or metastatic breast cancer	Name of Trial	
06/11/2014	16/10/2014 28/10/2014	Date of Receipt of Valid Research Application	
24/11/2014		Date of First NHS Patient Permission Recruited?	
No	Yes		
	25/11/2014 12	Date of E First V Patient Recruited P	
18		Duration between VRA and NHS Permission	
	28	Duration between NHS Permission and First Patient	cneck your dat
	40	- 5	negative.
		ition een Site Site cted Cted Date	ueis
		pate.	
No o	Yes		
		chmark	
		Date Site Site Selecte	
		HRA Approval d Date	
		Date Date HRA Confirmed Date Site Site Approval By Confirmed Selected Date Sponsor	
(0.7)	(O.T.	Date Site Confirmatic	
Please Select	Please Select	Non- Confirmatic Status	

63857	63856	63855	63854	63853
. 14/LO/1428	63856 14/LO/1476	63855 13/LO1691	14/LO/0203	63853 13/WA/0004
NHS Permission	NHS Permission	NHS Pemission	NHS Permission	NHS Permission
ASCOT: A phase 3 multicentre double-masked randomized controlled trial of adjunctive intraoccular and peri ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal	McCave Roche Trial BP29262 - CA Phase 11, Multicenter, Randomized, Double-Blind Study To Evaluate The efficacy And Safety of RO5520985 Plus Folfox Versus Bevacizumab Plus Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer.	ProCaid: An open phase 1/randomised, double-blind phase 11 study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy.	CLARITY: Clinical Efficacy and Mechanistic Evaluation of Affibercept for Proliferative Diabetic Retinopathy	placebo controlled clincial trial using Oral Steroids for the Resolution of ototis media with effusion (OME) in
13/10/2014	24/10/2014	02/04/2015	01/09/2014	05/11/2014
20/10/2014	18/11/2014	16/06/2015	24/10/2014	11/11/2014
Yes	Yes	Z o	Yes	Yes
19/05/2015	27/02/2015		29/06/2015 53	12/02/2015 6
7	25	75	55	
211	107		248	93
218	126		301	99
<u>Z</u>	Z o	Z O	N _O	Z
Please Select	Please Select	Please Select	Please Select	Please Select

				!
63861	63860	63859	63858	
15/LO/0016	63860 14/YH/1237	63859 14/NW1258	63858 11/NW/0246	
NHS Permission	NHS Permission	NHS Permission	NHS Permission	
MONARCH 3: A Randomised, Double-Bind, Placebo- Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6	FLAURA-1 - A phase 111, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Recep	ARAMIS 3104007 ORION - A multicentre, randomised, double-blind, placebo- controlled, phase 111 efficacy and safety study of ODM-201 in men with high risk non- metastatic castration- resistant prostate cancer.	STAR A randomised multi-stage II/III trial of standard first-line therapy (sunithib or pazopanib) comparing temporary cessation with allowing continuation in the treatment of locally advanced and/or metastatic renal cancer	surgery for open globe trauma.
29/04/2015	03/03/2015	02/04/2015	11/12/2014	
28/05/2015	31/03/2015	01/05/2015	22/12/2014	
Z.	Ύes	No	Yes	
29	01/05/2015 28	29	20/03/2015 11	
	& 	w w	8	
	59		99	
	Ύes	Z	Z o	
				_
Please Select	Please Select	Please Select	Please Select	
F **	:	: w	· ·	

<u>₩</u>		o o	σ.	0	
//ccfc+	3865 1	33864 1	33863 1	33862	
	63865 13/WM/0419	63864 13/EM/00395	63863 13/LO/1207	63862 13/LO/1557	
NHS	NHS Permission	NHS Permission	NHS Permission	NHS Permission	
Monoprost NHS Compared with	MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over: a randomised controlled trial	<u> </u>	STAR: StereoTactic radiotherapy for wet Age-Related macular degeneration: Randomised, double-masked, sham-controlled, clinical trial comparing low- voltage X-ray irradiation with as neede bevacizumab, to as needed bevacizumab monotherapy.	A A A A A A A A A A A A A A A A A A A	Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor- Positive, HER2
338.5 i.hmi	18/05/2015	28/01/2015	11/02/2015	21/04/2015	
	26/06/2015	17/03/2015	03/03/2015	21/05/2015	
748 Triestid-	N _o	N _o	Yes	Z o	
			27/04/2015 20		
	39	48		30	
			55		
			75		
8		, , , , , , , , , , , , , , , , , , ,			
Wit	N _o	N _o	N _o	N _o	
Within 70					
-					
Please	Please Select	Please Select	Please Select	Please Select	

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=33&SubmissionId=2734&TrustId=1119

	65117 1	35115	65111	65099	65098
	14/SC/0092	65115 14/SC/0171	14/WN/1055	65099 13/LO/1463	65098 13/EM/0348
	NHS Permission	NHS Permission	NHS Permission	NHS Permission	Permission
BMS-936558 A Safety Trial of Nivolumab (BMS-936558) in	LASER: Laminator Airflow in Severe Asthma for Exacerbation Reduction. A multi-centre, randomised, double-blind, parallel group trial of the effectiveness of the noctural use of a tempreture controlled Laminator Airflow (LTA) Device (Airsonett) in adults		AB12006 - A prospective, multicentre, randomized, double blind, placebo- controlled, 2- parallel group, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (linhotecan, 5- flurouracil and folinic acid) to placebo in com	InterAACT - A Multicentre Randomised Phase 11 Advanced Anal Cancer Trial	Lumigan in POA 11/09/2015 glaucoma/ocular hypertention
	30/06/2015	10/07/2015	10/07/2015	09/06/2015	11/09/2015
	07/07/2015	27/07/2015	23/07/2015	16/07/2015	11/09/2015
	Yes	No	N _O	8	No
	21/08/2015 7				
		17	13	37	0
	45				
	52				
	Yes	Z o	Z o	Z o	Days
	υ ס	υ υ	T O	(0.7)	
	Please Select	Please Select	Please Select	Please Select	Select

65118 15/LO/0691 65120 13/NS/0155 65119 14/LO/2061 NHS Permission NHS Permission NHS Permission Positioning In Macular Hole Surgery Trial - A multicentre interventional comparative randomised controlled clinical trial Progressed
During or After
Receiving At
Least One Prior Cancer Who Have Metastatic Non-Small Cell Lung positioning, with an inactive face-forward position on the outcome Systemic Regimen (CheckMate 153) Subjects With Advanced or of surgery for large macular holes. generation endometrial ablation for the treatment of HEALTH - A
multi-centre
randomised
controlled trial
comparing
laparoscopic
supra-cervical
hysterectomy
with second down comparing faceheavy menstrual 27/07/2015 08/09/2015 |17/09/2015 |No 22/08/2015 21/09/2015 03/09/2015 No No 38 30 Within 70 Days Within 70 Days Within 70 Days Please Select... Please Select... Please Select...

Showing records 1 to 23 of 23. Pages: 1

< Back

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by Exbos Limited the bespoke software specialists

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=33&SubmissionId=2734&TrustId=1119

